SCHEMBL5455924

SCHEMBL5455924

Cc1ccc(C(=O)Nc2sc3c(Cl)c(O)ccc3c2C(N)=O)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 11/20 0.54
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
GRIN2C Q14957 1/20 0.41
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
RECQL P46063 1/20 0.40
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456366 0.86 FLT3 (0.52) FLT3ALDH1A1HPGDGRIN2CRAB9A
SCHEMBL5466113 0.85 FLT3 (0.42) FLT3SMN1; SMN2ALDH1A1HPGDGRIN2C
SCHEMBL5453155 0.85 TAS1R3 (0.43) FLT3SMN1; SMN2RAB9ANPC1KCNQ3
SCHEMBL5447561 0.84 FLT3 (0.43) FLT3SMN1; SMN2ALDH1A1HPGDGRIN2C
SCHEMBL5458431 0.82 FLT3 (0.45) FLT3SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL5460181 0.81 GRIN2C (0.44) FLT3SMN1; SMN2ALDH1A1GRIN2CRAB9A
SCHEMBL5447128 0.80 FLT3 (0.42) FLT3SMN1; SMN2ALDH1A1HPGDGRIN2C
SCHEMBL5447136 0.80 FLT3 (0.44) FLT3SMN1; SMN2ALDH1A1HPGDGRIN2C
SCHEMBL5460130 0.80 FLT3 (0.42) FLT3ALDH1A1GRIN2CRAB9ANPC1
SCHEMBL5457764 0.80 ALDH1A1 (0.49) FLT3SMN1; SMN2ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885SMN1; SMN2 2157/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.